(NP (NP (NN Prevalence)) (PP (IN of) (NP (NP-COOD (NP (NN aneuploidy)) (, ,) (NP (JJ overexpressed) (NN ER)) (, ,) (CC and) (NP (JJ overexpressed) (NN EGFR))) (PP (IN in) (NP (NP (JJ random) (NN breast) (NNS aspirates)) (PP (IN of) (NP (NP (NNS women)) (PP (IN at) (NP (NP (ADJP-COOD (ADJP (JJ high)) (CC and) (ADJP (JJ low))) (NN risk)) (PP (IN for) (NP (NN breast) (NN cancer))))))))))) (. .))
(S (NP-SBJ-27 (NP (NN Breast) (NN tissue) (NNS biomarkers)) (SBAR (WHNP-28 (WDT which)) (S (NP-SBJ (-NONE- *T*-28)) (ADVP (RB accurately)) (VP (VBP predict) (NP (NP (NN breast) (NN cancer) (NN development)) (PP-TMP (IN within) (NP (DT a) (ADJP (CD 10) (NN year)) (NN period))) (PP (IN in) (NP (ADJP (JJ high) (NN risk)) (NNS women)))))))) (VP (VBP are) (UCP-COOD (VP (VBN needed) (NP (-NONE- *-27))) (CC but) (ADJP-PRD (ADVP-TMP (RB currently)) (RB not) (JJ available)))) (. .))
(S (NP-SBJ-29 (PRP We)) (VP (VBD initiated) (NP (DT this) (NN study)) (S (NP-SBJ (-NONE- *-29)) (VP (TO to) (VP (VB determine) (UCP-COOD (NP (LST (LS 1) (-RRB- -RRB-)) (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (QP (CD one) (CC or) (JJR more)) (NN breast) (NN tissue) (NNS abnormalities)) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NNS women)) (PP (IN at) (NP (NP (JJ high) (NN risk)) (PP (IN for) (NP (NN breast) (NN cancer)))))))))))) (, ,) (CC and) (SBAR (LST (LS 2) (-RRB- -RRB-)) (IN if) (S (NP-SBJ (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NN biomarker) (NNS abnormalities)))) (VP (VBZ is) (ADJP-PRD (ADJP (JJR greater)) (PP (-NONE- *ICH*-106))) (PP (IN in) (NP (JJ high) (NN risk) (NP (-NONE- *?*)))) (PP-106 (IN than) (FRAG (PP (IN in) (NP (JJ low) (NN risk) (NNS women))))))))))))) (. .))
(S (NP-SBJ (JJ Eligible) (JJ high) (NN risk) (NNS women)) (VP (VBD were) (NP-PRD (NP (DT those)) (PP (IN with) (NP (NP (DT a) (ADJP (JJ first) (NN degree)) (NN relative)) (PP (IN with) (NP-COOD (NP (NN breast) (NN cancer)) (, ,) (NP (JJ prior) (NN breast) (NN cancer)) (, ,) (CC or) (NP (JJ precancerous) (NN mastopathy)))))))) (. .))
(S (NP-SBJ (JJ Low) (NN risk) (NNS women)) (VP (VBD were) (NP-PRD (NP (DT those)) (PP (IN without) (NP-COOD (NP (DT these)) (CC or) (NP (JJ other) (JJ major) (JJ identifiable) (NN risk) (NNS factors)))))) (. .))
(S (NP-SBJ-30 (JJ Ductal) (NNS cells)) (VP (VBD were) (VP-COOD (VP (VBN obtained) (NP (-NONE- *-30)) (PP (IN via) (NP (JJ random) (JJ fine) (NN needle) (NNS aspirations)))) (CC and) (VP (ADVP (RB cytologically)) (VBN classified) (NP (-NONE- *-30))))) (. .))
(S (NP-SBJ (NNS Biomarkers)) (VP (VBD included) (NP-COOD (NP (NN DNA) (NN ploidy)) (, ,) (NP (NP (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))))) (. .))
(S (S-COOD (S (NP-SBJ-32 (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NN DNA) (NN aneuploidy)))) (VP (VBD was) (NP-PRD-33 (CD 30) (NN %)))) (, ,) (S (NP-SBJ=32 (NP (NN overexpression)) (PP (IN of) (NP (NN ER)))) (NP-PRD=33 (CD 10) (NN %))) (, ,) (CC and) (S (NP-SBJ=32 (NP (NN overexpression)) (PP (IN of) (NP (NN EGFR)))) (NP-PRD=33 (CD 35) (NN %)))) (, ,) (PP (IN in) (NP (NP (DT the) (CD 206) (JJ high) (NN risk) (NNS women)) (SBAR (WHNP-34 (NP (WP$ whose) (JJ median) (ADJP (CD 10) (NN year)) (NN Gail) (NP (NP (NN risk)) (PRN (-LRB- -LRB-) (NP (VBN projected) (NN probability)) (-RRB- -RRB-)))) (PP (IN of) (S (NP-SBJ (-NONE- *)) (VP (VBG developing) (NP (NN breast) (NN cancer)))))) (S (NP-SBJ (-NONE- *T*-34)) (VP (VBD was) (NP-PRD (CD 4.5) (NN %))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN prevalence)) (PP (IN of) (NP-COOD (NP (NN aneuploidy)) (CC and) (NP (JJ overexpressed) (NN EGFR))))) (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR higher)) (PP (-NONE- *ICH*-107))) (PP (IN in) (NP (DT the) (JJ high) (NN risk) (NNS women))) (PP-107 (IN than) (FRAG (PP (IN in) (NP (NP (NP (DT the) (CD 25) (JJ low) (NN risk) (NNS controls)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.002)))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP-35 (WP$ whose) (JJ median) (ADJP (CD 10) (NN year)) (NN Gail) (NN risk)) (S (NP-SBJ (-NONE- *T*-35)) (VP (VBD was) (NP-PRD (CD 0.7) (NN %)))))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NN ER) (NN overexpression))))) (PP (IN between) (NP (ADJP-COOD (ADJP (JJ high)) (CC and) (ADJP (JJ low))) (NN risk) (NNS groups)))) (VP (VBD was) (RB not) (ADVP (RB statistically)) (ADJP-PRD (JJ significant)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (VP (JJ =) (NP-PRD (CD 0.095)))) (-RRB- -RRB-))) (. .))
(S (NP-SBJ (DT This)) (VP (MD may) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP-COOD (NP (NP (DT the) (JJ low) (NN prevalence)) (PP (IN of) (NP (JJ overexpressed) (NN ER)))) (CC and) (NP (NP (DT the) (JJ small) (NN number)) (PP (IN of) (NP (NNS controls)))))))) (. .))
(S (NP-SBJ-36 (DT A) (JJ significant) (NN difference)) (VP (VBD was) (VP (VBN noted) (NP (-NONE- *-36)) (PP (IN in) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (QP (CD one) (CC or) (JJR more)) (JJ abnormal) (NNS biomarkers))))) (PP (IN between) (NP (DT the) (NP-COOD (NP (JJ high) (NN risk)) (CC and) (NP (JJ low) (NN risk))) (NNS women))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.001)))) (-RRB- -RRB-)))) (. .))
(S (NP-SBJ-37 (DT A) (JJ large) (JJ prospective) (NN trial)) (VP (VBZ is) (VP (VBN needed) (NP (-NONE- *-37)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP-SBJ (NP (QP (CD one) (CC or) (JJR more))) (PP (IN of) (NP (DT these) (NNS biomarkers)))) (, ,) (VP (VBZ is) (ADJP-PRD (JJ predictive) (PP (IN of) (NP (NN breast) (NN cancer) (NN development)))))))))))) (. .))
